Autoimmune disease, caused by unwanted immune responses to self-antigens, affects
millions of people each year and poses a great social and economic burden to individuals …

Regulatory T cell (Treg) therapy has shown promise in early clinical trials for treating graft-
versus-host disease, transplant rejection and autoimmune disorders. A challenge has been …

Antigen-specific regulatory T cells (Tregs) engineered with chimeric antigen receptors
(CARs) are a potent immunosuppressive cellular therapy in multiple disease models and …

Chimeric antigen receptor (CAR) technology can be used to engineer the antigen specificity
of regulatory T cells (Tregs) and improve their potency as an adoptive cell therapy in multiple …

Tregs expressing chimeric antigen receptors (CAR-Tregs) are a promising tool to promote
transplant tolerance. The relationship between CAR structure and Treg function was studied …

Regulatory T cells (Tregs) control immune homeostasis and prevent exacerbated immune
responses, and can be used as cell therapy to dampen a variety of autoimmune or …

The ability of the immune system to differentiate self from nonself is critical in determining the
immune response to antigens expressed on transplanted tissue. Even with conventional …

Cell-based therapy with CD4+ FOXP3+ regulatory T cells (Tregs) is a promising strategy to
limit organ rejection and graft-vs-host disease. Ongoing clinical applications have yet to …

Type 2 innate lymphoid cells (ILC 2s) are a subset of ILC s with critical roles in
immunoregulation. However, the possible role of ILC 2s as immunotherapy against allograft …

Regulatory T cells (Tregs) are potent suppressors of immune responses and are currently
being clinically tested for their potential to stop or control undesired immune responses in …